Valproic acid for agitation in dementia

Area of Science:

• Geriatric Medicine
• Psychopharmacology
• Clinical Trials

Background:

• Agitation is a common and challenging symptom in up to 70% of older adults with dementia.
• Valproic acid has been used for a decade to manage agitation in dementia, yet its efficacy lacks systematic review.
• This study critically examines existing randomized, placebo-controlled trials on valproic acid for agitation in dementia.

Purpose of the Study:

• To systematically evaluate the evidence supporting the use of valproic acid for treating agitation in individuals with dementia.
• To identify the efficacy and safety profile of valproic acid in this patient population.

Main Methods:

• A comprehensive search of the Cochrane Dementia and Cognitive Improvement Group's Specialized Register was conducted up to July 2003.
• Included were randomized, placebo-controlled trials with concealed allocation, assessing agitation and dementia.
• Data extraction and analysis focused on intention-to-treat principles, calculating odds ratios for treatment effects.

Main Results:

• Meta-analysis was precluded by methodological limitations in the included trials, including issues with allocation concealment and high dropout rates.
• One trial showed premature discontinuation due to adverse events, while another had questionable statistical analysis.
• Limited analysis of adverse effects indicated increased sedation and urinary tract infections in patients treated with valproic acid compared to controls.

Conclusions:

• The reviewed trials are considered preliminary, suggesting low-dose valproic acid is ineffective for dementia-related agitation.
• High-dose divalproex sodium was associated with an unacceptable incidence of adverse effects.
• Current evidence does not support the recommendation of valproate preparations for managing agitation in dementia; further research is warranted.